Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer

References

• Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10(1):10. doi:10.14740/wjon1166
   PubMedGoogle Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;1:2.
   Google Scholar
• Pelosi E, Castelli G, Testa U. Pancreatic cancer: molecular characterization, clonal evolution and cancer stem cells. Biomedicines. 2017;5(4):65. doi:10.3390/biomedicines5040065
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncologica. 2016;55(9–10):1158–1160. doi:10.1080/0284186X.2016.1197419
   PubMed Web of Science ®Google Scholar
• Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010;62(3):346–361. doi:10.1016/j.addr.2009.11.007
   PubMed Web of Science ®Google Scholar
• Manji GA, Olive KP, Saenger YM, Oberstein P. Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res. 2017;23(7):1670–1678. doi:10.1158/1078-0432.CCR-16-2319
   PubMed Web of Science ®Google Scholar
• Lei F, Xi X, Batra SK, Bronich TK. Combination therapies and drug delivery platforms in combating pancreatic cancer. J Pharmacol Exp Therapeutics. 2019;370(3):682–694. doi:10.1124/jpet.118.255786
   PubMed Web of Science ®Google Scholar
• Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer. 2014;14(1):1–13. doi:10.1186/1471-2407-14-471
   PubMedGoogle Scholar
• Aprile G, Negri FV, Giuliani F, et al. Second-line chemotherapy for advanced pancreatic cancer: which is the best option? Crit Rev Oncol Hematol. 2017;115:1–12. doi:10.1016/j.critrevonc.2017.03.025
   PubMedGoogle Scholar
• Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15(1):8–18. doi:10.1016/j.pan.2014.10.001
   PubMed Web of Science ®Google Scholar
• O’neil B, Scott A, Ma WW, et al. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015;26(9):1923–1929. doi:10.1093/annonc/mdv264
   PubMed Web of Science ®Google Scholar
• Erkan M, Hausmann S, Michalski CW, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9(8):454. doi:10.1038/nrgastro.2012.115
   PubMed Web of Science ®Google Scholar
• Kuninty PR, Bansal R, De Geus SW, et al. ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Sci Adv. 2019;5(9):eaax2770. doi:10.1126/sciadv.aax2770
   PubMed Web of Science ®Google Scholar
• Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem. 2007;101(4):887–907. doi:10.1002/jcb.21209
   PubMed Web of Science ®Google Scholar
• McCarroll JA, Naim S, Sharbeen G, et al. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol. 2014;5:141. doi:10.3389/fphys.2014.00141
   PubMed Web of Science ®Google Scholar
• Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol. 2016;13(12):750. doi:10.1038/nrclinonc.2016.119
   PubMed Web of Science ®Google Scholar
• Li J, Kataoka K. Chemo-physical strategies to advance the in vivo functionality of targeted nanomedicine: the next generation. J Am Chem Soc. 2020;143(2):538–559. doi:10.1021/jacs.0c09029
   PubMedGoogle Scholar
• Park J, Choi Y, Chang H, Um W, Ryu JH, Kwon IC. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics. 2019;9(26):8073. doi:10.7150/thno.37198
   PubMed Web of Science ®Google Scholar
• Wang AZ. EPR or no EPR? The billion-dollar question. Sci Transl Med. 2015;7(294):294ec112–294ec112. doi:10.1126/scitranslmed.aac8108
   Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Eng J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, Phase 3 trial. Lancet. 2016;387(10018):545–557. doi:10.1016/S0140-6736(15)00986-1
   PubMed Web of Science ®Google Scholar
• Kalra AV, Kim J, Klinz SG, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74(23):7003–7013. doi:10.1158/0008-5472.CAN-14-0572
   PubMed Web of Science ®Google Scholar
• Wang H, Mislati R, Ahmed R, et al. Elastography can map the local inverse relationship between shear modulus and drug delivery within the pancreatic ductal adenocarcinoma microenvironment. Clin Cancer Res. 2019;25(7):2136–2143. doi:10.1158/1078-0432.CCR-18-2684
   PubMedGoogle Scholar
• Nia HT, Munn LL, Jain RK. Mapping physical tumor microenvironment and drug delivery. Clin Cancer Res. 2019;25(7):2024–2026. doi:10.1158/1078-0432.CCR-18-3724
   PubMed Web of Science ®Google Scholar
• Li H-J, Du J-Z, Liu J, et al. Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration. ACS Nano. 2016;10(7):6753–6761. doi:10.1021/acsnano.6b02326
   PubMed Web of Science ®Google Scholar
• Cun X, Chen J, Li M, et al. Tumor-associated fibroblast-targeted regulation and deep tumor delivery of chemotherapeutic drugs with a multifunctional size-switchable nanoparticle. ACS Appl Mater Interfaces. 2019;11(43):39545–39559. doi:10.1021/acsami.9b13957
   PubMed Web of Science ®Google Scholar
• Li J, Han Y, Chen Q, et al. Dual endogenous stimuli-responsive polyplex micelles as smart two-step delivery nanocarriers for deep tumor tissue penetration and combating drug resistance of cisplatin. J Mater Chem B. 2014;2(13):1813–1824. doi:10.1039/C3TB21383H
   PubMedGoogle Scholar
• Li J, Ke W, Li H, Zha Z, Han Y, Ge Z. Endogenous stimuli‐sensitive multistage polymeric micelleplex anticancer drug delivery system for efficient tumor penetration and cellular internalization. Adv Healthcare Mater. 2015;4(15):2206–2219. doi:10.1002/adhm.201500379
   Google Scholar
• Li J, Wei K, Zuo S, et al. Light‐Triggered Clustered Vesicles with Self‐Supplied Oxygen and Tissue Penetrability for Photodynamic Therapy against Hypoxic Tumor. Adv Funct Mater. 2017;27(33):1702108. doi:10.1002/adfm.201702108
   Google Scholar
• Sun J, Wan Z, Chen Y, et al. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Acta biomaterialia. 2020;106:289–300. doi:10.1016/j.actbio.2020.01.039
   PubMedGoogle Scholar
• Lu T, Lokerse WJ, Seynhaeve AL, Koning GA, Ten Hagen TL. Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response. J Controlled Release. 2015;220:425–437. doi:10.1016/j.jconrel.2015.10.056
   PubMed Web of Science ®Google Scholar
• Lu T, Haemmerich D, Liu H, et al. Externally triggered smart drug delivery system encapsulating idarubicin shows superior kinetics and enhances tumoral drug uptake and response. Theranostics. 2021;11(12):5700. doi:10.7150/thno.55163
   PubMed Web of Science ®Google Scholar
• Li L, Hagen TL, Hossann M, et al. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. J Controlled Release. 2013;168(2):142–150. doi:10.1016/j.jconrel.2013.03.011
   PubMed Web of Science ®Google Scholar
• Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60(5):1197–1201.
   PubMed Web of Science ®Google Scholar
• Malekigorji M, Alfahad M, Lin PKT, Jones S, Curtis A, Hoskins C. Thermally triggered theranostics for pancreatic cancer therapy. Nanoscale. 2017;9(34):12735–12745. doi:10.1039/C7NR02751F
   PubMed Web of Science ®Google Scholar
• Emamzadeh M, Desmaële D, Couvreur P, Pasparakis G. Dual controlled delivery of squalenoyl-gemcitabine and paclitaxel using thermo-responsive polymeric micelles for pancreatic cancer. J Mater Chem B. 2018;6(15):2230–2239. doi:10.1039/C7TB02899G
   PubMed Web of Science ®Google Scholar
• Lo JH, Hao L, Muzumdar MD, et al. iRGD-guided tumor-penetrating nanocomplexes for therapeutic siRNA delivery to pancreatic cancer. Mol Cancer Ther. 2018;17(11):2377–2388. doi:10.1158/1535-7163.MCT-17-1090
   PubMedGoogle Scholar
• Wang G, Zhou Z, Zhao Z, et al. Enzyme-Triggered Transcytosis of Dendrimer–Drug Conjugate for Deep Penetration into Pancreatic Tumors. ACS Nano. 2020;14(4):4890–4904. doi:10.1021/acsnano.0c00974
   PubMed Web of Science ®Google Scholar
• Chen X, Zhou W, Liang C, et al. Codelivery nanosystem targeting the deep microenvironment of pancreatic cancer. Nano Lett. 2019;19(6):3527–3534. doi:10.1021/acs.nanolett.9b00374
   PubMedGoogle Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–322. doi:10.1016/j.ccr.2012.02.022
   PubMed Web of Science ®Google Scholar
• Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839–849. doi:10.1038/nrc1477
   PubMed Web of Science ®Google Scholar
• Schnittert J, Bansal R, Prakash J. Targeting pancreatic stellate cells in cancer. Trends Cancer. 2019;5(2):128–142. doi:10.1016/j.trecan.2019.01.001
   PubMed Web of Science ®Google Scholar
• Biffi G. Tracing the Origin of Fibroblasts in Pancreatic Cancer. Cell Mol Gastroenterol Hepatol. 2020;10(3):645. doi:10.1016/j.jcmgh.2020.06.008
   PubMedGoogle Scholar
• Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–596. doi:10.1084/jem.20162024
   PubMed Web of Science ®Google Scholar
• Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102–1123. doi:10.1158/2159-8290.CD-19-0094
   PubMed Web of Science ®Google Scholar
• Apte MV, Wilson JS, Lugea A, Pandol SJ. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology. 2013;144(6):1210–1219. doi:10.1053/j.gastro.2012.11.037
   PubMed Web of Science ®Google Scholar
• Liu H, Shi Y, Qian F. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Adv Drug Deliv Rev. 2021.
   Google Scholar
• Walter K, Omura N, Hong S-M, et al. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer–associated fibroblasts. Clin Cancer Res. 2010;16(6):1781–1789. doi:10.1158/1078-0432.CCR-09-1913
   PubMedGoogle Scholar
• Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res. 2008;14(19):5995–6004. doi:10.1158/1078-0432.CCR-08-0291
   PubMed Web of Science ®Google Scholar
• Bailey JM, Mohr AM, Hollingsworth MA. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene. 2009;28(40):3513–3525. doi:10.1038/onc.2009.220
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–1461. doi:10.1126/science.1171362
   PubMed Web of Science ®Google Scholar
• Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med. 2013;19(11):1410. doi:10.1038/nm.3389
   PubMed Web of Science ®Google Scholar
• Lee JJ, Perera RM, Wang H, et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proce Nat Acad Sci. 2014;111(30):E3091–E3100. doi:10.1073/pnas.1411679111
   PubMedGoogle Scholar
• Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735–747. doi:10.1016/j.ccr.2014.04.021
   PubMed Web of Science ®Google Scholar
• De Jesus-acosta A, Sugar EA, O’Dwyer PJ, et al. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br J Cancer. 2020;122(4):498–505. doi:10.1038/s41416-019-0683-3
   PubMed Web of Science ®Google Scholar
• Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2015;28(6):831–833. doi:10.1016/j.ccell.2015.11.002
   PubMed Web of Science ®Google Scholar
• Prakash J. Cancer-associated fibroblasts: perspectives in cancer therapy. Trends Cancer. 2016;2(6):277–279. doi:10.1016/j.trecan.2016.04.005
   PubMedGoogle Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. cell. 2002;110(6):673–687. doi:10.1016/S0092-8674(02)00971-6
   PubMed Web of Science ®Google Scholar
• Schnittert J, Bansal R, Storm G, Prakash J. Integrins in wound healing, fibrosis and tumor stroma: high potential targets for therapeutics and drug delivery. Adv Drug Deliv Rev. 2018;129:37–53. doi:10.1016/j.addr.2018.01.020
   PubMed Web of Science ®Google Scholar
• Schnittert J, Bansal R, Mardhian DF, Van Baarlen J, Östman A, Prakash J. Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. FASEB J. 2019;33(5):6609–6621. doi:10.1096/fj.201802336R
   PubMedGoogle Scholar
• Charrier A, Brigstock DR. Regulation of pancreatic function by connective tissue growth factor (CTGF, CCN2). Cytokine Growth Factor Rev. 2013;24(1):59–68. doi:10.1016/j.cytogfr.2012.07.001
   PubMed Web of Science ®Google Scholar
• Lali FV, Martin YH, Metcalfe AD. Advances in biopharmaceutical agents and growth factors for wound healing and scarring. Skin Tissue Eng Regen Med. 2016;14:337–355.
   Google Scholar
• Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M. Connective tissue growth factor–specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther. 2006;5(5):1108–1116. doi:10.1158/1535-7163.MCT-05-0516
   PubMedGoogle Scholar
• Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17(2):108–123. doi:10.1038/s41571-019-0281-6
   PubMed Web of Science ®Google Scholar
• Resovi A, Borsotti P, Ceruti T, et al. CCN-based therapeutic peptides modify pancreatic ductal adenocarcinoma microenvironment and decrease tumor growth in combination with chemotherapy. Cells. 2020;9(4):952. doi:10.3390/cells9040952
   PubMedGoogle Scholar
• Han H, Valdepérez D, Jin Q, et al. Dual enzymatic reaction-assisted gemcitabine delivery systems for programmed pancreatic cancer therapy. Acs Nano. 2017;11(2):1281–1291. doi:10.1021/acsnano.6b05541
   PubMed Web of Science ®Google Scholar
• Han H, Hou Y, Chen X, et al. Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy. J Am Chem Soc. 2020;142(10):4944–4954. doi:10.1021/jacs.0c00650
   PubMed Web of Science ®Google Scholar
• Duan W, Chen K, Jiang Z, et al. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Cancer Lett. 2017;385:225–233. doi:10.1016/j.canlet.2016.10.019
   PubMedGoogle Scholar
• Ilmer M, Westphalen CB, Niess H, et al. Repurposed drugs in pancreatic ductal adenocarcinoma: an update. Cancer J. 2019;25(2):134–138. doi:10.1097/PPO.0000000000000372
   PubMedGoogle Scholar
• Polydorou C, Mpekris F, Papageorgis P, Voutouri C, Stylianopoulos T. Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. Oncotarget. 2017;8(15):24506. doi:10.18632/oncotarget.15534
   PubMedGoogle Scholar
• Kozono S, Ohuchida K, Eguchi D, et al. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 2013;73(7):2345–2356. doi:10.1158/0008-5472.CAN-12-3180
   PubMed Web of Science ®Google Scholar
• Gao F, Wu J, Niu S, et al. Biodegradable, pH-sensitive hollow mesoporous organosilica nanoparticle (HMON) with controlled release of pirfenidone and ultrasound-target-microbubble-destruction (UTMD) for pancreatic cancer treatment. Theranostics. 2019;9(20):6002. doi:10.7150/thno.36135
   PubMed Web of Science ®Google Scholar
• Ji T, Lang J, Wang J, et al. Designing liposomes to suppress extracellular matrix expression to enhance drug penetration and pancreatic tumor therapy. ACS Nano. 2017;11(9):8668–8678. doi:10.1021/acsnano.7b01026
   PubMed Web of Science ®Google Scholar
• Senoo H, Mezaki Y, Fujiwara M. The stellate cell system (vitamin A-storing cell system). Anat Sci Int. 2017;92(4):387–455.
   PubMed Web of Science ®Google Scholar
• Froeling FE, Feig C, Chelala C, et al. Retinoic acid–induced pancreatic stellate cell quiescence reduces paracrine Wnt–β-catenin signaling to slow tumor progression. Gastroenterology. 2011;141(4):1486–1497. doi:10.1053/j.gastro.2011.06.047
   PubMed Web of Science ®Google Scholar
• Jaster R, Hilgendorf I, Fitzner B, et al. Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. Biochem Pharmacol. 2003;66(4):633–641. doi:10.1016/S0006-2952(03)00390-3
   PubMedGoogle Scholar
• Carapuça EF, Gemenetzidis E, Feig C, et al. Anti‐stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. J Pathol. 2016;239(3):286–296. doi:10.1002/path.4727
   PubMedGoogle Scholar
• Ene–Obong A, Clear AJ, Watt J, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013;145(5):1121–1132. doi:10.1053/j.gastro.2013.07.025
   PubMed Web of Science ®Google Scholar
• Han X, Li Y, Xu Y, et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem. Nat Commun. 2018;9(1):1–18. doi:10.1038/s41467-018-05906-x
   PubMedGoogle Scholar
• Kocher HM, Basu B, Froeling FE, et al. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun. 2020;11(1):1–9. doi:10.1038/s41467-020-18636-w
   PubMedGoogle Scholar
• Samuel CS, Bodaragama H, Chew JY, Widdop RE, Royce SG, Hewitson TD. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension. 2014;64(2):315–322. doi:10.1161/HYPERTENSIONAHA.114.03594
   PubMed Web of Science ®Google Scholar
• Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology. 2004;145(9):4125–4133. doi:10.1210/en.2004-0209
   PubMed Web of Science ®Google Scholar
• Mardhian DF, Storm G, Bansal R, Prakash J. Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. J Controlled Release. 2018;290:1–10. doi:10.1016/j.jconrel.2018.09.031
   PubMed Web of Science ®Google Scholar
• Hu M, Wang Y, Xu L, et al. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat Commun. 2019;10(1):1–13. doi:10.1038/s41467-019-10893-8
   PubMedGoogle Scholar
• Kuninty PR, Schnittert J, Storm G, Prakash J. MicroRNA targeting to modulate tumor microenvironment. Front Oncol. 2016;6:3. doi:10.3389/fonc.2016.00003
   PubMed Web of Science ®Google Scholar
• Kadera BE, Li L, Toste PA, et al. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One. 2013;8(8):e71978. doi:10.1371/journal.pone.0071978
   PubMed Web of Science ®Google Scholar
• Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. Mol Therapy. 2013;21(5):986–994. doi:10.1038/mt.2013.35
   PubMed Web of Science ®Google Scholar
• Tang X, Hou Y, Yang G, et al. Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death Differ. 2016;23(1):132–145. doi:10.1038/cdd.2015.78
   PubMedGoogle Scholar
• Diaz-Riascos ZV, Ginesta MM, Fabregat J, et al. Expression and role of microRNAs from the miR-200 family in the tumor formation and metastatic propensity of pancreatic cancer. Mol Therapy Nucleic Acids. 2019;17:491–503. doi:10.1016/j.omtn.2019.06.015
   PubMedGoogle Scholar
• Kota J, Hancock J, Kwon J, Korc M. Pancreatic cancer: stroma and its current and emerging targeted therapies. Cancer Lett. 2017;391:38–49. doi:10.1016/j.canlet.2016.12.035
   PubMedGoogle Scholar
• Kuninty PR, Bojmar L, Tjomsland V, et al. MicroRNA-199a and-214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. Oncotarget. 2016;7(13):16396. doi:10.18632/oncotarget.7651
   PubMedGoogle Scholar
• Schnittert J, Kuninty PR, Bystry TF, Brock R, Storm G, Prakash J. Anti-microRNA targeting using peptide-based nanocomplexes to inhibit differentiation of human pancreatic stellate cells. Nanomedicine. 2017;12(12):1369–1384. doi:10.2217/nnm-2017-0054
   PubMed Web of Science ®Google Scholar
• Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7(3):2078–2089. doi:10.1021/nn3043463
   PubMed Web of Science ®Google Scholar
• Chen X, Jia F, Li Y, et al. Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment. Biomaterials. 2020;246:119999. doi:10.1016/j.biomaterials.2020.119999
   PubMed Web of Science ®Google Scholar
• De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24–37. doi:10.1038/nrc1782
   PubMed Web of Science ®Google Scholar
• Jayasingam SD, Citartan M, Thang TH, Mat Zin AA, Ang KC, Ch’ng ES. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol. 2020;9:1512. doi:10.3389/fonc.2019.01512
   PubMed Web of Science ®Google Scholar
• Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206–221. doi:10.1016/j.addr.2017.04.010
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):1–12. doi:10.1186/s13045-017-0430-2
   PubMedGoogle Scholar
• Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):1–16. doi:10.1186/s13045-019-0760-3
   PubMedGoogle Scholar
• Zhang T, Hao H, Zhou X-Y. The role of lipoxin in regulating tumor immune microenvironments. Prostaglandins Other Lipid Mediat. 2019;144:106341. doi:10.1016/j.prostaglandins.2019.106341
   PubMedGoogle Scholar
• Zhou M, Chen B, Sun H, Deng Z, Andersson R, Zhang Q. The protective effects of Lipoxin A4 during the early phase of severe acute pancreatitis in rats. Scand J Gastroenterol. 2011;46(2):211–219. doi:10.3109/00365521.2010.525715
   PubMed Web of Science ®Google Scholar
• Zong L, Li J, Chen X, et al. Lipoxin A4 attenuates cell invasion by inhibiting ROS/ERK/MMP pathway in pancreatic cancer. Oxid Med Cell Longev. 2016;2:2016.
   Google Scholar
• Zong L, Chen K, Jiang Z, et al. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. J Exp Clin Cancer Res. 2017;36(1):1–12. doi:10.1186/s13046-017-0655-5
   PubMedGoogle Scholar
• Simoes R, De‐Brito N, Cunha‐Costa H, et al. Lipoxin A4 selectively programs the profile of M2 tumor‐associated macrophages which favour control of tumor progression. Int j Cancer. 2017;140(2):346–357. doi:10.1002/ijc.30424
   PubMedGoogle Scholar
• De-brito NM, Da-costa HC, Simões RL, Barja-Fidalgo C. Lipoxin-Induced Phenotypic Changes in CD115+ LY6Chi Monocytes TAM Precursors Inhibits Tumor Development. Front Oncol. 2019;9:540. doi:10.3389/fonc.2019.00540
   PubMedGoogle Scholar
• Gkretsi V, Zacharia LC, Stylianopoulos T. Targeting inflammation to improve tumor drug delivery. Trends Cancer. 2017;3(9):621–630. doi:10.1016/j.trecan.2017.07.006
   PubMed Web of Science ®Google Scholar
• Cui X-J, He Q, Zhang J-M, Fan H-J, Wen Z-F, Qin Y-R. High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. Pancreas. 2014;43(1):135–140. doi:10.1097/MPA.0b013e3182a8d41f
   PubMed Web of Science ®Google Scholar
• Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999;59(17):4356–4362.
   PubMed Web of Science ®Google Scholar
• Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5(8):2018–2024.
   PubMedGoogle Scholar
• Juuti A, Louhimo J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol. 2006;59(4):382–386. doi:10.1136/jcp.2005.026831
   PubMedGoogle Scholar
• Matsubayashi H, Infante JR, Winter JM, et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther. 2007;6(10):1569–1575. doi:10.4161/cbt.6.10.4711
   PubMed Web of Science ®Google Scholar
• Čeponytė U, Paškevičiūtė M, Petrikaitė V. Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures. Cancer Manag Res. 2018;10:1543. doi:10.2147/CMAR.S163747
   PubMed Web of Science ®Google Scholar
• Lyons TR, O’brien J, Borges VF, et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med. 2011;17(9):1109–1115. doi:10.1038/nm.2416
   PubMed Web of Science ®Google Scholar
• Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3(8):1309–1316.
   PubMed Web of Science ®Google Scholar
• Li S, Xu H-X, Wu C-T, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019;22(1):15–36. doi:10.1007/s10456-018-9645-2
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–231. doi:10.1016/j.ccr.2009.01.027
   PubMed Web of Science ®Google Scholar
• Ribatti D. Antiangiogenic therapy accelerates tumor metastasis. Leukemia Research. 2011;35(1):24–26. doi:10.1016/j.leukres.2010.07.038
   PubMedGoogle Scholar
• Yin T, He S, Ye T, Shen G, Wan Y, Wang Y. Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis. Transl Oncol. 2014;7(2):221–229. doi:10.1016/j.tranon.2014.02.007
   PubMedGoogle Scholar
• Terry S, Savagner P, Ortiz‐Cuaran S, et al. New insights into the role of EMT in tumor immune escape. Mol Oncol. 2017;11(7):824–846. doi:10.1002/1878-0261.12093
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27(13):2231–2237. doi:10.1200/JCO.2008.20.0238
   PubMed Web of Science ®Google Scholar
• Sahai V, Saif MW, Kalyan A, et al. A Phase I/II open-label multicenter single-arm study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in patients with metastatic pancreatic cancer. J Pancreatic Cancer. 2019;5(1):35–42. doi:10.1089/pancan.2019.0012
   PubMedGoogle Scholar
• Shen Y, Wang X, Lu J, et al. Reduction of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal cancer. Cancer Cell. 2020;37(6):800–817. doi:10.1016/j.ccell.2020.05.005
   PubMedGoogle Scholar
• Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–120. doi:10.1136/gutjnl-2012-302529
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–429. doi:10.1016/j.ccr.2012.01.007
   PubMed Web of Science ®Google Scholar
• Komar G, Kauhanen S, Liukko K, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res. 2009;15(17):5511–5517. doi:10.1158/1078-0432.CCR-09-0414
   PubMed Web of Science ®Google Scholar
• Martin JD, Seano G, Jain RK. Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu Rev Physiol. 2019;81:505–534. doi:10.1146/annurev-physiol-020518-114700
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Munn LL, Jain RK. Reengineering the tumor vasculature: improving drug delivery and efficacy. Trends Cancer. 2018;4(4):258–259. doi:10.1016/j.trecan.2018.02.010
   PubMed Web of Science ®Google Scholar
• Nagathihalli NS, Castellanos JA, Shi C, et al. Signal transducer and activator of transcription 3, mediated remodeling of the tumor microenvironment results in enhanced tumor drug delivery in a mouse model of pancreatic cancer. Gastroenterology. 2015;149(7):1932–1943. doi:10.1053/j.gastro.2015.07.058
   PubMed Web of Science ®Google Scholar
• Kim SJ, Jung KH, Son MK, et al. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery. Cancer Lett. 2017;403:339–353. doi:10.1016/j.canlet.2017.06.035
   PubMed Web of Science ®Google Scholar
• Trindade A, Djokovic D, Gigante J, Mendonça L, Duarte A. Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo. BMC Cancer. 2017;17(1):1–13. doi:10.1186/s12885-017-3171-2
   PubMedGoogle Scholar
• Hamzah J, Jugold M, Kiessling F, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008;453(7193):410–414. doi:10.1038/nature06868
   PubMed Web of Science ®Google Scholar
• Wei Y, Song S, Duan N, et al. MT1‐MMP‐Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy. Adv Sci. 2020;7(17):1902746. doi:10.1002/advs.201902746
   Google Scholar
• Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487–505. doi:10.1038/s41575-020-0300-1
   PubMed Web of Science ®Google Scholar
• Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015;21(15):3561–3568. doi:10.1158/1078-0432.CCR-14-1051
   PubMed Web of Science ®Google Scholar
• Laklai H, Miroshnikova YA, Pickup MW, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2016;22(5):497–505. doi:10.1038/nm.4082
   PubMed Web of Science ®Google Scholar
• Thompson CB, Shepard HM, O’Connor PM, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther. 2010;9(11):3052–3064. doi:10.1158/1535-7163.MCT-10-0470
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Harris WP, Beck JT, et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res. 2016;22(12):2848–2854. doi:10.1158/1078-0432.CCR-15-2010
   PubMed Web of Science ®Google Scholar
• Tempero MA, Van Cutsem E, Sigal D, et al. HALO 109-301: a randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20)+ nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). Am Soc Clin Oncol. 2020;1:587.
   Google Scholar
• Bever KM, Sugar EA, Bigelow E, et al. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. Hpb. 2015;17(4):292–298. doi:10.1111/hpb.12334
   PubMedGoogle Scholar
• Chen Y, Kim J, Yang S, et al. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell. 2021.
   Google Scholar
• Zinger A, Koren L, Adir O, et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors. ACS Nano. 2019;13(10):11008–11021. doi:10.1021/acsnano.9b02395
   PubMed Web of Science ®Google Scholar